|
市場調查報告書
藥品供應鏈策略：重新評價針對改善節省成本及供應鏈管理的產品通路
Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain management
| 出版商 |
Datamonitor |
| 出版日期 |
2008年03月 |
商品編碼 |
64548 |
| 內容資訊 |
英文 64 pages |
| 價格 |
|
|
本報告已在2011年07月19日停止出版。
藥品通路中存在各種仲介業者，容易增加出現偽藥的風險，給製造商的銷售業績造成重大打擊。
本報告書內容包括：歐洲及美國藥品通路模式概要、供應鏈動向及主要企業、影響利害關係人的重要事件等。內容綱要摘記如下：
第1章 實施概要
第2章 供應鏈概要
- 關於藥物供應鏈的顧慮
- 美國的供應鏈
- 英國的供應鏈
- 美國及EU的藥物通路的差別
第3章 藥物非正式管道流通
- 美國的灰色市場
- 歐洲的平行貿易
- 針對非正式流通的策略
第4章 供應鏈動向
- 市場發展
- 智慧財產權及EU的發展
- 藥物登記
- EU的平行貿易
- 範圍超過EU的平行貿易的影響
- 委託製造
- 藥物複雜化使得通路的需求也更加複雜化
- 整合動向
- 壓力愈來愈大的批發產業
- PBM商業的侵入
- 自創品牌的成長
- 藥局商店法的鬆綁
- 美國及EU通路的差別
- 美國零售業者不太與批發業者分享利潤
- 美國製造業者支撐通路系統
- 歐洲零售產業力量不強
第5章 參考資料
附錄
Abstract
Overview
Introduction
Ideally drug supply should be a simple and transparent chain that connects the
manufacturer and patient in as few steps as possible, however in practice it
can be a highly circuitous one that includes several intermediaries before
reaching a pharmacy. This increases the risk of counterfeit drugs and
facilitates parallel trade, both leading to lost sales for the manufacturer.
Scope
- An overview of the drug supply chain in Europe and the US.
- Identification of the key players in the drug supply chain.
- Coverage of recent trends and key events in the distribution industry.
- Analysis of the impact of new events on the key stakeholders.
Report Highlights
With the trend towards market expansion, higher drug volumes must be
transported further, necessitating the use of logistics coordination on a
global scale. As distribution needs increase, the knock-on effect of
state-enforced cost-containment strategies are reducing already tight margins,
forcing many stakeholders to change their strategy.
Manufacturers are looking to gain greater control over the drug supply chain,
to safeguard it against counterfeit entry, but also to regulate drug supply
and therefore limit diversion. The most progressive events have occurred in
the UK, where Pfizer has implemented direct to pharmacy distribution, with
other companies likely to follow suit.
Competitive pressures have and will continue to drive consolidation along the
supply chain, with vertical integration providing a means of extending control
and limiting margin loss. A relaxation in pharmacy laws in Europe will lead to
an increase of chains, while wholesaler-pharmacy and manufacturer-pharmacy
combinations are becoming common.
Reasons to Purchase
- Gain an understanding of the pharmaceutical supply chain in the US and
Europe, and who the key players are.
- Become aware of new issues in the distribution industry, and how they
influence the major stakeholders.
- Gain an insight into current trends in distribution, and how they are
likely to change going forward.
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the report
- Key findings
- CHAPTER 2 SUPPLY CHAIN OVERVIEW
- Why worry about the drug supply chain?
- The US Supply Chain
- Manufacturers wield most power in setting drug price in the US
- Wholesalers are the primary buyers for manufacturers
- Pharmacies are at the interface of the supply chain and patient
- Pharmacy Benefits Managers - a crucial link in the US supply chain
- The UK Supply Chain
- Drug list price is regulated by the PPRS
- Wholesalers compete to acquire pharmacist contracts
- The government reimburses pharmacists at list price
- Differences in drug distribution between the US and EU
- CHAPTER 3 DRUG DIVERSION
- The grey market in the US
- The illegal importation of drugs into the US
- Parallel trade in Europe
- Counterfeits enter UK via parallel trade channels
- EU focus on parallel trade and counterfeit drug link
- Strategies to tackle diversion
- Greater regulation of the pharmaceutical supply chain
- e-pedigree roll out in 2009 in California
- Drug supply restrictions are effective but can lead to domestic
shortfalls
- Dual pricing initiatives
- Tighter supply chains - direct to pharmacy distribution is gaining
traction
- GSK sets the ball rolling in the UK
- Pfizer goes further by introducing exclusive distribution
- Sanofi-Aventis and AstraZeneca introduce DTP in the UK
- Implications of the DTP scheme for the UK
- CHAPTER 4 THE SUPPLY CHAIN GOING FORWARD
- Market expansion
- Intellectual property and European Union expansion
- Drug registration
- Parallel trade in the European Union
- Parallel trade implications beyond the EU
- Manufacture outsourcing
- More complex drugs with more complex distribution needs
- The trend towards consolidation
- Wholesale industry under increasing pressure
- Infiltration of the PBM business
- Innovators fail to make PBM acquisitions a success
- CVS and Caremark merger
- Wal-Mart' s foray into pharmacy benefit management
- Growth in private label brands
- Relaxation in pharmacy outlet laws
- Differences between US versus EU distribution
- US retailers leave wholesalers with little net margin
- US manufacturers subsidize distribution
- European retailers have less power
- CHAPTER 5 BIBLIOGRAPHY
- Publications and online articles
- Datamonitor resources
- APPENDIX
- Abbreviations
- Exchange rates
- List of Tables
- Table 1: Exchange rates, 2007
- List of Figures
- Figure 1: Drug and monetary flow in the US supply chain
- Figure 2: The UK pharmaceutical supply chain
- Figure 3: UK retail pharmacies, 2006
- Figure 4: US pharmaceutical grey market
- Figure 5: Drivers and strategies to tackle, drug diversion
- Figure 6: UK pharmaceutical distribution channels
- Figure 7: Expansion of wholesaler services
- Figure 8: Factors impacting on the future drug supply chain
- Figure 9: Consolidation within the supply chain
|
